Jan 23 (Reuters) - Regenxbio Inc:
* REGENXBIO ENHANCES GENE THERAPY MANUFACTURING CAPABILITIES BY ENTERING INTO STRATEGIC PARTNERSHIP WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES
* REGENXBIO-UNDER TERMS REGENXBIO GAINS GUARANTEED CAPACITY FOR SUPPLY OF NAV AAV DRUG SUBSTANCE MANUFACTURED UNDER CGMP AT LARGE SCALE FOR THREE YEARS Source text for Eikon: Further company coverage:
 